News

This study highlighted that both PASI scores and systemic inflammation, assessed using GlycA levels, were linked with cardiovascular disease.

A recent study suggests ketamine can significantly improve symptoms of PTSD and OCD—but this is based on a review of an insufficient number of randomized controlled trials.

Kavish Patidar, DO, explains how socioeconomic status and healthcare delivery impact outcomes in patients with acute kidney injury and cirrhosis.

With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.

FDA grants Rare Pediatric Disease, Fast Track designations to gildeuretinol, aiming to accelerate treatment for Stargardt disease.

In this analysis, the investigators systematically assessed links between the macronutrient profiles of common allergenic foods and corresponding prevalence of food allergy.

A study identified homelessness and minority status as factors that impact clozapine prescription patterns.

In part 2 of this 2-part discussion, hosts discuss ethical considerations and the growing evidence base around euthanasia and medical assistance in dying.

In part 1 of this 2-part discussion, hosts explore the ethical foundation and background of euthanasia and medically-assisted suicide.

The sNDA was intended to include positive two-year data in the US Prescribing Information for avacincaptad pegol based on the GATHER2 clinical trial.

The supplemental Biologics License Application is supported by the phase 3 ASTRO study of guselkumab SC induction therapy in ulcerative colitis.

Following the publication of the new RLS recommendations, HCPLive spoke with John Winkelman, MD, PhD, chair of the AASM committee that revised the guidelines.

This meta-analysis showed that both secondary closure techniques substantially reduce the risk of hidradenitis suppurativa recurrence compared to primary direct closure.

Birgit Vogel, MD discusses racial inequities and geographic variations in peripheral artery disease care in the United States.

The investigators concluded that chronic psychological stress substantially impacts skin homeostasis and, consequently, skin aging.

Lawitz explains issues with traditional FXR agonists for MASH treatment and how FXR314 differs, potentially offering a more safe and efficacious option.

Milind Desai, MD describes favorable real-world safety outcomes from mavacamten use over 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program.

HCPLive spoke with Kastl at NASPGHAN about the team’s study on the immune response to the COVID-19 vaccination among children with IBD.

Loomba reviews safety and efficacy data for the thyroid hormone receptor beta agonist from a phase 2a trial presented at AASLD The Liver Meeting 2024.

Ahmad Masri, MD, MS, discusses data from the FOREST-HCM trial examining effects of aficamten in patients with oHCM eligible for septal reduction therapy at baseline.

These retrospective, 52-week data highlight the efficacy and safety of bimekizumab for those with moderate-to-severe psoriasis.

Ahmad Masri, MD, MS, discusses a study from AHA 2024 detailing changing risk profiles and outcomes in trials among patients with ATTR-CM.

In this episode, hosts break down a pair of studies from AHA 2024, BPROAD and SUMMIT, as well as a study in JAMA projecting semaglutide eligibility in US adults.

Stephen Nicholls, MBBS, PhD, provides additional insight into KRAKEN trial data and the potential of muvalaplin.

Marianna Fontana, MD, PhD discusses Phase 1 interim results on the CRISPR-based gene-editing therapy, nex-z, for ATTR-CM.

This analysis evaluated the frequency of peanut-sensitized infants and toddlers being sensitized to other types of nuts.

Stephen J. Nicholls, MD, PhD discusses the robust efficacy and tolerability of zerlasiran for Lp(a) lowering, paving the way for Phase 3 development.

UCB has announced the FDA’s approval of bimekizumab, also known as Bimzelx, for patients with moderate-to-severe HS.